Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies

 Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies

Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies

Shots:

  • Bicycle to receive $1.7B including $30M upfront, development & commercialization milestones and royalties on sales of Bicycle based immuno-oncology therapies against multiple targets which will be commercialized by Genentech
  • Bicycle will conduct discovery research and early pre-clinical development phase up to candidate selection while Genentech will further develop and commercialize the therapies, post-selection of candidates
  • The collaboration leverages Bicycle’s discovery platform and the expertise of both the companies to identify novel therapies for multiple immuno-oncology targets

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Genentech

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post